The first adjuquis four-price influenza vaccine! The European Union has approved Fluad Quadrivalent (aQIV) to fight off seasonal influenza for the age of 65!

, June 09, 2020 /PRNewswire-BIOON/ -- Seqirus, a company owned by Australian biopharmaceutical giant CSL Group, is a global leader in influenza preventionRecently, the company announced that the European Commission (EC) has approved the first adjuvantinfluenza vaccine
Fluad Quadrivalent (aQIV,influenza vaccine, adjectomy) to be available throughout Europe to protect the population aged 65 and over from four seasonal influenza strains, including two influenza A strains and two influenza B strainsThe current trivalent vaccine consists of 2 A strains and 1 B strainapproval is the first step in providing aQIV to Europe in the 2021/22 flu seasonThe European Centre for Disease Control and Prevention estimates that between 15,000 and 70,000 people die each year in Europe from flu-related complications, and it encourages annual vaccinations as the most effective way to prevent influenza
in the U.S., Fluad Quadrivalent was approved in February as the first adjulatedinfluenza vaccinein the U.Smarket to help older people 65 and older to fight off seasonal influenzaAccording to the U.SCenters for Disease Control and Prevention (CDC), individuals over six months of age should receive an annual flu vaccine , but this is especially important for those 65 and older who are at risk of severe flu complications seasonal influenza is a common, highly sexually transmitted infectious disease that can have a serious impact on older people aged 65 and over, with higher hospitalization and mortality rates than young, healthy adults In the United States, 70 percent of flu-related hospitalizations and 90 percent of flu-related deaths occur in the age group 65 and older during the 2017/18 flu season In this population, the effectiveness of influenza vaccines is also often lower, due to the age-related decline in immune function, which reduces the body's ability to produce an adequate and protective immune response to the vaccine Fluad Quadrivalent (aQIV) uses the same proven MF59® (aTIV, trivalent influenza vaccine) as fluadd (aTIV, trivalent influenza vaccine) adjorizer technology to produce a powerful, broad and long-lasting immune response Fluad Quadrivalent (aQIV) adds an additional strain of influenza B virus compared to Fluad (aTIV) Fluad (aTIV) is a long-used adjulated trivalent influenza vaccine, which has distributed and distributed more than 100 million doses in several countries around the world since it was first approved in 1997 Fluad (aTIV) showed higher efficacy in people 65 and older than standard non-adjulated trivalent influenza vaccines Fluad Quadrivalent (aQIV) consists of two influenza A strains and two influenza B strains, while Fluad (aTIV) consists of two A strains and one B strain in Europe, Fluad Quadrivalent (aQIV) will be produced by Seqirus's vaccine manufacturing plant in Liverpool, UK When Fluad (aTIV) was the leading vaccine recommended by people aged 65 and over in the UK during the 2018/2019 flu season, an analysis by Public Health England showed that the overall adjusted influenza vaccine was 62 per cent (3.4 per cent, 85.0 per cent) effective for influenza confirmed in medical laboratories In the most recent flu season before 2018/19, all age groups aged 18 and over in the UK were vaccinated against non-adjuvative influenza, and the 65-year-old sage age group tended to be less effective than the 18-64 age group an additional type B strain added to Fluad Quadrivalent (aQIV) provides additional coverage, especially during the flu season, where the B strain is more dominant, such as the 2017/18 flu season In the intensive care unit that reported data to the European Centers for Disease Control and Prevention during the flu season, nearly half of all flu deaths were caused by the B virus older people's immune systems naturally decline with age, making them more susceptible to the flu Aging also reduces the body's immune response to the flu vaccine Adjorizers added to aQIV are designed to enhance the immune response in older adults and help compensate for this effect Dr Raja Rajaram, head of European medical affairs at seqirus, , said: "In this day and age, even more than ever, having vaccines for all age groups to help prevent influenza We know that vaccinated people are less likely to get the flu This may help to reduce the pressure on the health care system during the continuing focus on COVID-19 As a company focused on developing vaccines, we are committed to providing better protection for people who are particularly susceptible to influenza We are pleased to be able to bring this vaccine to Europe, which will provide medical professionals with an additional tool at the forefront of influenza prevention "
(biovalleybioon.com) original source: First adjuvanted quadrivalent quadrodd influenza received vaccineeu eu app roval